A single agent trial of FLX 787 for treatment of cramps associated with amyotrophic lateral sclerosis (ALS)

Trial Profile

A single agent trial of FLX 787 for treatment of cramps associated with amyotrophic lateral sclerosis (ALS)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs FLX 787 (Primary)
  • Indications Amyotrophic lateral sclerosis; Cramp
  • Focus Therapeutic Use
  • Sponsors Flex Pharma
  • Most Recent Events

    • 02 Aug 2017 According to a Flex Pharma media release, the company expects important data readouts from this study in 2018.
    • 25 Jul 2017 According to Flex Pharma media release, the company will end the exploratory Australian ALS study early, with roughly a dozen patients
    • 13 Sep 2016 According to Flex Pharma media release, status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top